Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
2.260
-0.080 (-3.42%)
Streaming Delayed Price
Updated: 2:54 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
January 04, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
January 04, 2024
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
December 19, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Leadership Change
December 18, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
December 11, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
December 10, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Host Virtual KOL Event on Lacutamab
November 27, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
November 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
November 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
October 27, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma 2024 Financial Calendar
October 19, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
October 16, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
October 09, 2023
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 05, 2023
Via
Benzinga
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
October 05, 2023
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201...
Via
Benzinga
Exposures
Product Safety
Innate Pharma Provides Update on Lacutamab Clinical Program
October 05, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
September 22, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Half 2023 Financial Results and Business Update
September 14, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
August 29, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
August 10, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
July 11, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
July 07, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
June 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
June 16, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
June 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
June 10, 2023
From
Innate Pharma SA
Via
Business Wire
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
June 08, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
June 07, 2023
From
Innate Pharma SA
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.